148 related articles for article (PubMed ID: 15940853)
1. Takings issues in the approval of generic biologics.
Yoo JC
Food Drug Law J; 2005; 60(1):33-43. PubMed ID: 15940853
[No Abstract] [Full Text] [Related]
2. Generic drugs: the stalling game.
Consum Rep; 2001 Jul; 66(7):36-40. PubMed ID: 11725791
[TBL] [Abstract][Full Text] [Related]
3. GATT implementation and generic drug approval.
Safir PO; Lassman SM
Food Drug Law J; 1996; 51(2):295-302. PubMed ID: 11820203
[No Abstract] [Full Text] [Related]
4. The generic drug approval process.
Rheinstein PH
Am Fam Physician; 1993 Dec; 48(8):1357-60. PubMed ID: 8249762
[No Abstract] [Full Text] [Related]
5. The ability of current biologics law to accommodate emerging technologies.
Carter MJ
Food Drug Law J; 1996; 51(3):375-80. PubMed ID: 11797714
[No Abstract] [Full Text] [Related]
6. Draft guidance for industry on developing medical imaging drugs and biologics; availability--FDA. Availability of guidance.
Fed Regist; 1998 Oct; 63(198):55067-9. PubMed ID: 10185833
[TBL] [Abstract][Full Text] [Related]
7. United States Food and Drug Administration requirements for approval of generic drug products.
Meyer MC
J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
[TBL] [Abstract][Full Text] [Related]
8. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked?
Shulman SR; Brown JS
Food Drug Law J; 1995; 50(4):503-31. PubMed ID: 10343017
[No Abstract] [Full Text] [Related]
9. Recent developments help the defense of drug companies in 10b-5 cases.
Salpeter AN; Hutchins H
Food Drug Law J; 1996; 51(3):345-53. PubMed ID: 11797711
[No Abstract] [Full Text] [Related]
10. The FDA and "privatization"--the drug approval process.
Rutherford EM
Food Drug Law J; 1995; 50 Spec():203-25. PubMed ID: 10343044
[No Abstract] [Full Text] [Related]
11. Generic substitution: issues for problematic drugs.
Henderson JD; Esham RH
South Med J; 2001 Jan; 94(1):16-21. PubMed ID: 11213935
[TBL] [Abstract][Full Text] [Related]
12. Biological products regulated under Section 351 of the Public Health Service Act; implementation of biologics license; elimination of establishment license and product license; public workshop--FDA. Proposed rule; notice of workshop.
Fed Regist; 1998 Aug; 63(154):42773-4. PubMed ID: 10182565
[TBL] [Abstract][Full Text] [Related]
13. Initial responses to recommendations of the Blue Ribbon Committee on Generic Medicines.
Heller WM
Am J Hosp Pharm; 1993 Feb; 50(2):318-22. PubMed ID: 8480792
[No Abstract] [Full Text] [Related]
14. Current issues in the pioneer versus generic drug wars.
Safir PO
Food Drug Law J; 1995; 50(2):335-9. PubMed ID: 10343002
[No Abstract] [Full Text] [Related]
15. Generic drug product equivalence: current status.
Meyer MC
Am J Manag Care; 1998 Aug; 4(8):1183-9; quiz 1190-2. PubMed ID: 10182892
[TBL] [Abstract][Full Text] [Related]
16. FDA's role in making exclusivity determinations.
Dickinson EH
Food Drug Law J; 1999; 54(2):195-203. PubMed ID: 11758573
[No Abstract] [Full Text] [Related]
17. FDA's role in administering the Hatch-Waxman Act.
Malkin BJ
Food Drug Law J; 1999; 54(2):211-4. PubMed ID: 11758575
[No Abstract] [Full Text] [Related]
18. Entry decisions in the generic pharmaceutical industry.
Morton FM
Rand J Econ; 1999; 30(3):421-40. PubMed ID: 10558596
[TBL] [Abstract][Full Text] [Related]
19. CBER status on reform initiatives: industry reactions and comments.
Page M
Food Drug Law J; 1997; 52(2):193-6. PubMed ID: 10557559
[No Abstract] [Full Text] [Related]
20. Multisource drugs: implications and concerns in the geriatric population.
Gerbino PP; Joseph AS
Hosp Pharm; 1993 Feb; 28(2):96-8, 101-2. PubMed ID: 10125706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
